Seite Sophie, Benech Florence, Berdah Sandrine, Bayer Muriel, Veyrat Sophie, Segot Evelyne, Sakalikova Marcela, Gibejova Lucia, Zelenkova Hana
J Drugs Dermatol. 2013 Aug;12(8):920-4.
The objective of these studies was to investigate whether a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water formulated in a highly protective packaging can have an impact in the management of rosacea-prone skin subjects.
Several studies were performed to evaluate the efficacy of this product in the management of rosacea prone skin, as either monotherapy or adjunctive therapy or to maintain the efficacy of a Metronidazole treatment. The first study was performed on 37 women aged 18-45 with added stage 2 erythro-couperosis, who applied test formula as monotherapy twice a day for 4 weeks. During a second study, a dermatological evaluation was performed on patients with stage I or II rosacea, a questionnaire containing information about patient characteristics, tolerance, clinical signs, symptoms and skin reactivity to "trigger factors" was completed by dermatologists at baseline and 2 months after treatment with the test formula as either monotherapy or adjunctive therapy. Finally, in a third study, 65 patients finishing a Metronidazole treatment applied once daily and the tested formula twice daily were divided into 2 groups using the test formula or vehicle control, twice a day for 8 weeks for the evaluation of efficacy as adjunctive therapy.
We noted that the test formula, as an adjunctive therapy, helped prolong the efficacy of a Metronidazole treatment. In monotherapy, there was a significant efficacy of the test formula associated with an excellent tolerance. A significant improvement of all the clinical signs and symptoms of rosacea and a reduction of the skin reactivity to "trigger factors" were shown.
These studies highlight the interest value and impact of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water formulated in a highly protective packaging in monotherapy or in combination with or after a therapeutic treatment in the management of patients suffering from rosacea.
这些研究的目的是调查一种含有安波酚、神经敏感素和理肤泉温泉水且采用高度防护包装的护肤品，对玫瑰痤疮易患皮肤受试者的治疗是否有影响。
进行了多项研究，以评估该产品作为单一疗法、辅助疗法治疗玫瑰痤疮易患皮肤的疗效，或维持甲硝唑治疗的疗效。第一项研究针对37名年龄在18至45岁之间、患有2期红斑毛细血管扩张型玫瑰痤疮的女性，她们将测试配方作为单一疗法，每天使用两次，持续4周。在第二项研究中，对I期或II期玫瑰痤疮患者进行了皮肤科评估，皮肤科医生在基线时以及使用测试配方作为单一疗法或辅助疗法治疗2个月后，完成了一份包含患者特征、耐受性、临床体征、症状以及皮肤对“触发因素”反应性信息的问卷。最后，在第三项研究中，65名完成甲硝唑治疗的患者被分为两组，一组每天使用一次测试配方，另一组每天使用两次测试配方，作为辅助疗法，每天两次，持续8周以评估疗效。
我们注意到，测试配方作为辅助疗法，有助于延长甲硝唑治疗的疗效。在单一疗法中，测试配方具有显著疗效，且耐受性良好。玫瑰痤疮的所有临床体征和症状均有显著改善，皮肤对“触发因素”的反应性降低。
这些研究突出了一种含有安波酚、神经敏感素和理肤泉温泉水且采用高度防护包装的护肤品，在单一疗法中，或与治疗玫瑰痤疮的疗法联合使用或在其之后使用时，对玫瑰痤疮患者治疗的价值和影响。
